Dunoyer Makes Leap To CFO As AZ’s BD Overhaul Continues
As AstraZeneca’s global product chief Marc Dunoyer moves on to the CFO job, he leaves a newly restructured, active, and decentralized dealmaking organization.
You may also be interested in...
Equipped with 19 drug candidates for Phase III trials over the next two years, Britain’s AstraZeneca says it’s finally “on a roll.” But the troubled medicine maker still expects earnings to keep falling in 2014 amid uncertainty over heart drug Brilinta and likely generic competition to Nexium in the U.S.
AstraZeneca agreed to pay $200 million upfront and $240 million in predefined milestones for Spirogen to enhance its early oncology pipeline with linked tumor-targeted antibody drug conjugates. The company simultaneously announced a collaboration with ADC Therapeutics to jointly develop ADCs.
Deal brings AstraZeneca’s biologics subsidiary an anti-PD1 monoclonal antibody that could enter clinical trials this autumn. MedImmune will pay $225 million for the privately held biotech, with milestones of up to $275 million possible down the line.